News | October 27, 2021
Cipla consolidated net profit at Rs 711.36 cr. in Q2FY22
Cipla has reported consolidated financial results for the period ended September 30, 2021
Cipla has reported consolidated financial results for the period ended September 30, 2021
Torrent Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
The list of kids with co-morbidities eligible for vaccination would be announced by the government
ANG Lifesciences India Limited has reported financial results for the period ended September 30, 2021
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
The platform has seen an overall growth of 84% in the number of people seeking consultations for skin-related issues
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
Subscribe To Our Newsletter & Stay Updated
